Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 in HER2 Expressing Advanced Gastric/Gastroesophageal Junction Cancer
NCT03925974Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- Jun 2019
- Primary completion
- May 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Alphamab Oncology. Started Jun 2019; status: completed.
02
Drugs
anbenitamab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03925974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925974.